In a move aimed to bolster its immuno-oncology program, Eli Lilly and Company has acquired Armo BioSciences for $50 per share, or approximately $1.6bn.
Agilent's 15,000-square-foot expansion will increase its capacity to meet a growing demand for next-generation sequencing products from its genomics group.
Researchers at the Wyss Institute are teaming up with Cellectis to develop “ultra-safe” human cells resistant to infection – which could enable more effective ways to manufacture protein therapeutics, vaccines, and cell therapies.
GE Healthcare Life Sciences has launched an updated, flexible cell processing system designed to rapidly and effectively harvest cells for treatments, including CAR T-cell therapy.
GE Healthcare Life Sciences has launched a prefabricated, modular bioprocessing facility designed for the manufacture of viral vector-based therapeutics.
Bluebird Bio and Celgene Corporation are collaborating to make a CAR T-cell therapy for patients with relapsed and refractory multiple myeloma in the US.
